According to a recent LinkedIn post from HistoSonics, the company is highlighting the first patient treatments in the WOLVERINE feasibility trial using its Edison Histotripsy System for benign prostatic hyperplasia at Prince of Wales Hospital in Hong Kong. The post notes that BPH affects millions of men and suggests histotripsy may offer a non‑invasive alternative to more invasive procedures and longer recoveries.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post also underscores management’s view that this milestone supports broader ambitions to apply histotripsy technology to a range of serious clinical conditions. For investors, the early use of Edison in a new indication and geography may signal pipeline diversification, potential future revenue streams, and growing clinical validation in the MedTech and urology treatment markets.